CAS: 1173699-31-4

AMG 337 is a small molecule inhibitor, which is derived from synthetic chemical processes, with a mode of action involving the selective inhibition of the c-Met receptor tyrosine kinase. The c-Met receptor, also known as hepatocyte growth factor receptor, plays a critical role in various cellular processes such as proliferation, survival, and motility. Dysregulation of c-Met signaling is implicated in several types of cancers, making it a significant therapeutic target. This inhibitor competitively binds to the ATP-binding site of the c-Met receptor, thus preventing its autophosphorylation and subsequent activation of downstream signaling pathways. By inhibiting these pathways, AMG 337 can impede the growth and spread of tumor cells that are reliant on aberrant c-Met signaling. AMG 337 has been primarily studied for its applications in the treatment of cancers, such as gastric and esophageal cancers, where c-Met overexpression or mutation is observed. Research has explored its efficacy in both monotherapy and in combination with other therapeutic agents, aiming to enhance anti-tumor activity. As a potent inhibitor of c-Met, AMG 337 offers a promising therapeutic strategy for targeting malignancies driven by this receptor.

AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).

AMG-337

Applications AMG 337 is a potent and selective inhibitor of mesencymal epethelial transition factor (MET factor) which has been implicated in several cancers. References Boezio, A. et al.: J. Med. Chem., 59, 2326 (2016);

(R)-6-(1-(8-Fluoro-6-(1-Methyl-1H-Pyrazol-4-Yl)-[1,2,4]Triazolo[4,3-A]Pyridin-3-Yl)Ethyl)-3-(2-Methoxyethoxy)-1,6-Naphthyridin-5(6H)-One